NIKKEI 225
37,697.11 -762.97 (-1.98%) HANG SENG
17,242.19 +40.92 (+0.24%) CRUDE OIL
82.95 +0.14 (+0.17%) GOLD FUTURES
2,328.70 -9.70 (-0.41%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,468.11 -2,176.30 (-4.06%)
Xencor, Inc. (XNCR)
After hours:
| Previous close | 18.37 |
| Open | 18.39 |
| Bid | 19.00 x 300 |
| Ask | 19.08 x 200 |
| Day's range | 18.08 - 19.11 |
| 52-week range | 16.49 - 28.96 |
| Volume | |
| Avg. volume | 714,535 |
| Market cap | 1.163B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
- Business Wire
Xencor to Present at Upcoming Investor Conferences
PASADENA, Calif., February 28, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:
- Business Wire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
PASADENA, Calif., February 27, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined
